An isolated monoclonal anti-Siglec-7 antibody, wherein the anti-Siglec-7 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein: (a) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 18, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 31, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44, an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 57, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 70, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 83; (b) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 13, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 26, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 39, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 52, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 65, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 78; (c) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 15, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 41, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 67, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 80; (d) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 29, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81; or (e) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 32, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 45, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 71, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 84. (a) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 18, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 31, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 44, an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 57, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 70, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 83; (b) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 13, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 26, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 39, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 52, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 65, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 78; (c) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 15, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 28, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 41, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 54, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 67, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 80; (d) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 29, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81; or (e) the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 19, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 32, an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 45, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 71, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 84.